Bio-Rad Lab

Q2 FY2026 EarningsQ2 FY2026 results delivered a significant top-and-bottom-line beat against consensus: non-GAAP revenue reached $651.0M (+4.3% vs. $624.0M expected), and normalized EPS was $2.62 (+50.1% vs. $1.75 expected). While Life Science revenue remains soft (-4.1% YoY), Clinical Diagnostics grew 2.6% YoY, and digital PCR revenue surged over 20%. Management reaffirmed its FY2026 outlook, balancing ongoing academic research headwinds with steady diagnostics demand.